MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/100/0.1/20.12.24 | Real-time Bid/Ask 14:13:25 21/06/2024 BST | ||
| 0.058 EUR / 0.08 EUR | +1.47% |
|
| Current month | +11.48% | ||
| 1 month | +54.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 0.058 | -14.71% |
| 20/06/24 | 0.068 | +21.43% |
| 19/06/24 | 0.056 | -18.84% |
| 18/06/24 | 0.069 | -8.00% |
| 17/06/24 | 0.075 | -5.06% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 11:37 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MB3KH3 |
| ISIN | DE000MB3KH38 |
| Date issued | 10/02/2023 |
| Strike | 100 $ |
| Maturity | 20/12/2024 (182 Days) |
| Parity | 10 : 1 |
| Emission price | 0.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.3 € |
|---|---|
| Lowest since issue | 0.004 € |
| Spread | 0.022 € |
| Spread % | 27.50% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.00%
- Stock Market
- Warrants
- Warrant
